Emerging therapies for heart failure: renal mechanisms and effects (Q37783956)

23 August 2017

title

Emerging therapies for heart failure: renal mechanisms and effects (English)

1 reference

23 August 2017

0 references

Amir Kazory

1 reference

23 August 2017

Edward A. Ross

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20803357

3 July 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20803357

3 July 2024

publication date

1 January 2012

1 reference

full work available at URL

23 August 2017

http://link.springer.com/content/pdf/10.1007/s10741-010-9191-5.pdf

1 reference

https://api.crossref.org/works/10.1007/S10741-010-9191-5

http://link.springer.com/article/10.1007/s10741-010-9191-5/fulltext.html

3 July 2024

1 reference

https://api.crossref.org/works/10.1007/S10741-010-9191-5

http://link.springer.com/content/pdf/10.1007/s10741-010-9191-5

3 July 2024

1 reference

DOI

https://api.crossref.org/works/10.1007/S10741-010-9191-5

3 July 2024

published in

Heart Failure Reviews

1 reference

23 August 2017

1 reference

23 August 2017

1 reference

23 August 2017

page(s)

1-16

1 reference

Heart Disease and Stroke Statistics--2008 Update: A Report From the American Heart Association Statistics Committee and Stroke Statistics Subcommittee

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

A comprehensive view of sex-specific issues related to cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Adenosine and kidney function: potential implications in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Effects of BG9719 (CVT-124), an A1-adenosine receptor antagonist, and furosemide on glomerular filtration rate and natriuresis in patients with congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Cardio-renal effects of the A1 adenosine receptor antagonist SLV320 in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

The effect of KW-3902, an adenosine A1 receptor antagonist, on renal function and renal plasma flow in ambulatory patients with heart failure and renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

The effects of KW-3902, an adenosine A1-receptor antagonist,on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Effects of multiple oral doses of an A1 adenosine antagonist, BG9928, in patients with heart failure: results of a placebo-controlled, dose-escalation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

The adenosine A1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Activation of adenosine A1 receptor attenuates cardiac hypertrophy and prevents heart failure in murine left ventricular pressure-overload model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Intracellular signaling pathways for norepinephrine- and endothelin-1-mediated regulation of myocardial cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Endothelin as a regulator of cardiovascular function in health and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Endothelin binding to cultured calf adrenal zona glomerulosa cells and stimulation of aldosterone secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

RITZ-5: randomized intravenous TeZosentan (an endothelin-A/B antagonist) for the treatment of pulmonary edema: a prospective, multicenter, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Clinical effects of endothelin receptor antagonism with bosentan in patients with severe chronic heart failure: results of a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

A pilot safety trial of prolonged (48 h) infusion of the dual endothelin-receptor antagonist tezosentan in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

The dual endothelin receptor antagonist tezosentan acutely improves hemodynamic parameters in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Tezosentan (an intravenous endothelin receptor A/B antagonist) reduces peripheral resistance and increases cardiac power therefore preventing a steep decrease in blood pressure in patients with congestive heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Hemodynamic and neurohumoral effects of selective endothelin A (ET(A)) receptor blockade in chronic heart failure: the Heart Failure ET(A) Receptor Blockade Trial (HEAT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

The hemodynamic and neurohormonal effects of low doses of tezosentan (an endothelin A/B receptor antagonist) in patients with acute heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Comparison of the dual receptor endothelin antagonist enrasentan with enalapril in asymptomatic left ventricular systolic dysfunction: a cardiovascular magnetic resonance study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Role of endothelin-1 in clinical hypertension: 20 years on.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Hormones and hemodynamics in heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Acute hemodynamic effects of conivaptan, a dual V(1A) and V(2) vasopressin receptor antagonist, in patients with advanced heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Prognostic importance of elevated jugular venous pressure and a third heart sound in patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Raised venous pressure: a direct cause of renal sodium retention in oedema?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Peripherally inserted veno-venous ultrafiltration for rapid treatment of volume overloaded patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Use of a novel ultrafiltration device as a treatment strategy for diuretic resistant, refractory heart failure: initial clinical experience in a single center

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

A randomized, controlled trial of the renal effects of ultrafiltration as compared to furosemide in patients with acute decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Comparison of ultrafiltration, nesiritide, and usual care in acute decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Early ultrafiltration in patients with decompensated heart failure and diuretic resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Outcomes of volume-overloaded cardiovascular patients treated with ultrafiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Impact of ultrafiltration on renal function in patients with decompensated heart failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Ultrafiltration for decompensated heart failure: renal implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Fluid overload in acute heart failure--re-distribution and other mechanisms beyond fluid accumulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Importance of venous congestion for worsening of renal function in advanced decompensated heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Drawbacks and prognostic value of formulas estimating renal function in patients with chronic heart failure and systolic dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Nutritional and anti-inflammatory interventions in chronic heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Mechanisms of pulmonary edema clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Nesiritide — Not Verified

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Endothelin inhibits renin release from isolated rat glomeruli

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10741-010-9191-5

Endothelin is a potent secretagogue for atrial natriuretic peptide in cultured rat atrial myocytes

21 January 2018

1 reference

12 December 2020

Large volume ultrafiltration for acute decompensated heart failure using standard peripheral intravenous catheters

1 reference

12 December 2020

Neurohormonal prediction of mortality following admission for decompensated heart failure

1 reference

12 December 2020

Ultrafiltration does not affect certain predictors of outcome in heart failure

1 reference

12 December 2020

Need for a unified decision-making tool for ultrafiltration therapy in heart failure; call for action

1 reference

12 December 2020

Prognostic value of plasma endothelin-1 in patients with chronic heart failure

1 reference

12 December 2020

Plasma adenosine levels increase in patients with chronic heart failure

1 reference

12 December 2020

Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction

1 reference

12 December 2020

Endothelin synthesis by rat inner medullary collecting duct cells.

1 reference

12 December 2020

Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients

1 reference

12 December 2020

Regulated Overexpression of the A 1 -Adenosine Receptor in Mice Results in Adverse but Reversible Changes in Cardiac Morphology and Function

1 reference

12 December 2020

Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD)

1 reference

12 December 2020

Identifiers

DOI

1 reference

23 August 2017

1 reference